OM
OM.US Outset Medical Inc
- Market cap
- USD 70.4M
- P/E
- -
- P/B
- 0.85x
- ROE
- -82.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OM.US undervalued?
Graham numberThe Graham number of Outset Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Outset Medical Inc fundamental analysis
No fundamental analysis for Outset Medical Inc yet.
Outset Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Outset Medical Inc
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub…
Full company profileOutset Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Outset Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 2.01M | 15.1M | 49.9M | 103M | 115M | 130M | 114M | 119M | 124M |
| Gross Profit | -6.12M | -17.8M | -13.0M | 7.61M | 17.8M | 29.0M | 38.6M | 46.8M | 52.1M |
| Operating Income | -46.6M | -70.3M | -117M | -131M | -161M | -170M | -113M | -66.7M | -59.8M |
| EBITDA | -44.0M | -62.1M | -114M | -125M | -154M | -154M | -102M | -62.4M | -52.4M |
| Net Income | -49.8M | -68.3M | -121M | -132M | -163M | -173M | -128M | -81.7M | -68.9M |
| EPS | -25 | -34 | -42 | -43 | -51 | -52 | -37 | -5.37 | -3.66 |
| Balance Sheet | |||||||||
| Total Assets | 151M | 88.4M | 404M | 463M | 400M | 314M | 276M | 264M | 230M |
| Total Liabilities | 439M | 461M | 75.2M | 89.4M | 154M | 191M | 249M | 138M | 147M |
| Shareholders' Equity | -288M | -372M | 329M | 374M | 246M | 123M | 26.8M | 127M | 83.3M |
| Cash & Short-term Investments | 143M | 70.1M | 315M | 339M | 288M | 203M | 159M | 169M | 137M |
| Total Debt | 28.9M | 29.1M | 38.6M | 37.8M | 103M | 136M | 202M | 101M | 105M |
| Cash Flow | |||||||||
| Operating Cash Flow | -46.4M | -70.3M | -99.0M | -130M | -146M | -131M | -116M | -46.3M | -43.8M |
| Capital Expenditure | 1.77M | 3.29M | 9.11M | 3.11M | 8.33M | 3.44M | 912K | 798K | 380K |
| Free Cash Flow | -48.2M | -73.6M | -108M | -133M | -154M | -135M | -117M | -47.1M | -44.2M |
| Ratios | |||||||||
| ROE | - | - | -36.7% | -35.3% | -66.2% | -140.6% | -477.2% | -64.3% | -82.7% |
| ROA | -32.9% | -77.3% | -29.9% | -28.5% | -40.7% | -55.1% | -46.4% | -30.9% | -29.9% |
| Net Profit Margin | -2,480.3% | -453.0% | -241.7% | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% | -55.5% |
| Debt to Equity | - | - | 0.12x | 0.10x | 0.42x | 1.11x | 7.53x | 0.80x | 1.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Outset Medical Inc dividends
Outset Medical Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:15 on Mar 20, 2025.
Who owns Outset Medical Inc
- Insiders 5.85%
- Institutions 70.47%
- Public & others 23.68%
- Shares outstanding 18.9M
- Free float 14.6M
Top funds holding OM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Health Care | 1.52M | 8.37% | 0.00% | Aug 2026 |
| Fidelity Advisor Health Care I | 800K | 4.40% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 553K | 3.04% | 0.00% | Sep 2026 |
| Fidelity VIP Health Care Initial | 280K | 1.54% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 87.7K | 0.48% | +56.49% | Sep 2026 |
| C WorldWide Healthcare Select 1A | 66.7K | 0.37% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 52.6K | 0.29% | 0.00% | Oct 2026 |
| AQR Delphi L/S Eq IAU1F | 46.6K | 0.26% | 0.00% | Mar 2026 |
| Dimensional US Small Cap ETF | 37.2K | 0.20% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 36.1K | 0.20% | 0.00% | Sep 2026 |
| Fidelity Disruptive Medicine ETF | 34.0K | 0.19% | 0.00% | Oct 2026 |
| AQR Small Cap Multi-Style I | 31.9K | 0.18% | -12.74% | Jun 2026 |
| Fidelity Series Total Market Index | 27.7K | 0.15% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 26.7K | 0.15% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 24.3K | 0.13% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 2 ETF | 24.3K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 14.5K | 0.08% | 0.00% | Aug 2026 |
| T. Rowe Price Extended Equity Market Idx | 13.8K | 0.08% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 13.0K | 0.07% | +152.96% | Jun 2026 |
| DFA U.S. Small Cap I | 12.9K | 0.07% | 0.00% | Sep 2026 |
Top institutions holding OM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 2.74M | 15.10% | +0.04% | Jun 2026 |
| BML Capital Management LLC | 2.52M | 13.87% | 0.00% | Sep 2026 |
| AQR Capital Management LLC | 999K | 5.50% | +23.59% | Jun 2026 |
| Perceptive Advisors LLC | 833K | 4.59% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 780K | 4.29% | +2.14% | Jun 2026 |
| Assenagon Asset Management SA | 679K | 3.74% | +34.67% | Jun 2026 |
| Bank of America Corp | 666K | 3.66% | -29.87% | Jun 2026 |
| Partner Fund Management LP | 582K | 3.20% | -2.10% | Jun 2026 |
| Ensign Peak Advisors Inc | 434K | 2.39% | -17.52% | Jun 2026 |
| BlackRock Inc | 418K | 2.30% | -66.89% | Jun 2026 |
| Peapod Lane Capital LLC | 332K | 1.83% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 212K | 1.17% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 205K | 1.13% | -51.43% | Jun 2026 |
| Stratos Wealth Partners, LTD | 201K | 1.10% | 0.00% | Jun 2026 |
| UBS Group AG | 190K | 1.05% | -24.64% | Jun 2026 |
| Acadian Asset Management LLC | 189K | 1.04% | +439.24% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 182K | 1.00% | +7.40% | Jun 2026 |
| Millennium Management LLC | 182K | 1.00% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 173K | 0.95% | +85.80% | Jun 2026 |
| Jane Street Group LLC | 139K | 0.77% | +114.78% | Jun 2026 |
Outset Medical Inc company profile
- Company name
- Outset Medical Inc
- Ticker
- OM.US
- Exchange
- USA Stocks
- Listed since
- Sep 15, 2020
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 310
- Fiscal year end
- December
- Address
- 3052 Orchard Drive, San Jose, CA, United States, 95134
- Phone
- 669 231 8200
- Website
- outsetmedical.com
About Outset Medical Inc
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Outset Medical Inc management
9- Ms. Leslie L. TriggPresident, CEO & Chairman · born 1971
- Ms. Renee M. GaetaCFO, Principal Financial Officer & Principal Accounting Officer · born 1981
- Sara MuellerVice President of Marketing & Sales Effectiveness
- Dr. Michael Aragon M.D.Chief Medical Officer
- Dinamarie StefaniSenior Vice President of Regulatory Affairs & Quality Assurance
- Ms. Brittni McGillChief Nursing Officer
- Mr. Brett FoggSenior Vice President of R&D & Operations
- Mr. Derick ElliottExecutive Vice President of Commercial
- Mr. Jaime PulidoSenior Vice President of Finance